35 Drug Products Pass Consistency Evaluation: Betapharma, Jichuan Pharma, Grand Pharmaceutical, Qilu Pharma, Humanwell Among Key Players

Sep 08, 2023 20:31 CST Updated 20:31

Jumpcan

Developer and Manufacturer of Chinese and Western Medicine and Health Products

Qilu Pharmaceutical

Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer

According to the delivery information of two batches of drug approval certificates released by NMPA on September 8, 2023, 35 varieties(48 Specifications)Latest approval, involvingBetter, Jumpcan, Grand Pharmaceutical, Qilu Pharmaceutical, RenfuAnd many other pharmaceutical companies.

Among them,Atomoxetine Hydrochloride Oral SolutionWelcomeJumpcan, Anhui Xinshiji Pharmaceutical Co.,Ltd.Approved on the same day;Carglumic Acid Dispersible Tablets, Dolutegravir Sodium Tablets, Sodium Valproate Injection ConcentrateAndω-3 Fish Oil Fat Emulsion InjectionFour drugs, including [drug names], have welcomed their first companies to pass the evaluation. For details, see the table below and the mini-program.

09.08 Approved Varieties (Marked in Red for the First Approval)

Data Source:PharmCube Approved Drugs Summary Database

END

Recent Popular Resource Acquisition

Reply to the keyword "Report", access dozens of exclusive reports produced by Pharma Intelligence
Reply to the keyword "CSCO", Obtain 2023 CSCO Guidelines
Reply to the keyword "ASCO", Obtain 2023 ASCO Abstract by Cancer Type
Reply to the keyword "First Generic in 2022", Obtain the list of first generic drugs approved in 2022
Reply to the keyword "Medical Insurance", obtain the 2022 medical insurance catalog

Contact us to experience more professional services from PharmaCloud.

WillDiscussion

CombineWork

GardenDistrict

TakeWu

Database

Consultation

Customized

Service

Media

Cooperation

ClickReadRead the original text, apply for a free trial of PharmaCloud Enterprise Edition!